Abstract:OBJECTIVE:To explore the effects of pravastatin in prevention of diabetes and mechanisms thereof. METHODS:1183 to 4-week-old female non-obese diabetic (NOD) mice were randomly divided into 4 groups: control group (n = 30), fed with regular diet, low-dose pravastatin group (n = 29), fed with 1 mg kg(-1) d(-1) pravastatin via the diet, medium-dose pravastatin group (n =29) fed with 10 mg kg(-1) d(-1) pravastatin via the diet, and high-dose pravastatin group (n = 30), fed with 40 mg kg(-1) d(-1) pravastatin via the diet. The mice were followed up till they were 30-week old. Urine glucose was measured every week. Eight 12-week old mice without onset of DM from each group were killed with the pancreas taken out to undergo insulitis scoring via microscopy. Another 8 12-week old mice without onset of DM from each group were killed with their spleens taken out. Suspension of splenocytes was made, put into a 96-well plate, and stimulated by rGAD65; and [3SH]-thymidine was incorporated. The stimulation index (SI) of the splenocytes was calculated. Flow cytometry was used to observe the population of CD4 CD25+ regulatory T cells. ELISA was used to detect the interferon (IFN)-gamma and interleukin (IL)-4 levels in the supernatants of splenocytes. RT-PCR was used to detect the mRNA expression of IFN-gamma and IL4 in the spleen. RESULTS:At 30 weeks of age, the incidence rate of DM onset of the high-dose pravastatin group was significantly lower than that of the control group (P = 0.003), and the incidence rates of DM onset of the medium and low dose groups were not significantly different from that of the control group (both P >0.05). The severity of insulitis at 12 weeks of age of the high-dose pravastatin group was significantly lower than that of the controls group (P <0.001). There were no significant difference in the SI level and in the percentage of CD4+ CD25+ regulatory T cells among the four groups (all P >0.05). The IFN-gamma level in the supernatant of splenocytes of the high-dose pravastatin group was (42 + 20) pg/ml, significantly lower than that of the control group [(157 + 32) pg/ml, P = 0.000]. The IFN-gamma mRNA expression level in the spleen of the high-dose pravastatin group was 0.24 +/- 0.10, significantly lower than that of the control group (0.81 +/- 0.18, P =0.000). The IL-4 level in the supernatants of splenocytes of the high-dose pravastatin group was S (91 +/- 22) pg/m, significantly higher than that of the control group [(44 +/- 20) pg/ml, P=0.000)]. The IL4 mRNA expression level in spleen of the high-dose pravastatin group was 0.39 +/- 0.18, significantly higher than that of the control group (0.20 +/- 0.08, P = 0.002). However, there were not significant differences in the IFN-gamma and IL-4 levels in the supernatant and the IFN-gamma and IL-4 mRNA expression in spleen among the medium dose, low dose, and control groups (all P >0.05). CONCLUSION:High-dose pravastatin therapy at early time decreases the IFN-gamma level and increases the IL-4 level, shifts the immune response to the direction of Th2, and subsequently lessens insulitis and prevents DM.

Co-administration of Paroxetine and Pravastatin Causes Deregulation of Glucose Homeostasis in Diabetic Rats Via Enhanced Paroxetine Exposure

Co-Administration Of Paroxetine Increased The Systemic Exposure Of Pravastatin In Diabetic Rats Due To The Decrease In Liver Distribution

Differential Effects of Pravastatin on the Pharmacokinetics of Paroxetine in Normal and Diabetic Rats

Paroxetine Decreased Plasma Exposure of Glyburide Partly Via Inhibiting Intestinal Absorption in Rats

Quercetin Improves Glucose and Lipid Metabolism of Diabetic Rats: Involvement of Akt Signaling and SIRT1

Ganoderma Lucidum Polysaccharides Exert Anti-Hyperglycemic Effect On Streptozotocin-Induced Diabetic Rats Through Affecting Beta-Cells

Fluoxetine Regulates Glucose and Lipid Metabolism Via the PI3K‑AKT Signaling Pathway in Diabetic Rats.

Clinical review of paroxetine in type 2 diabetes mellitus patients with anxiety and depression

[Effects of Pravastatin in Prevention of Diabetes and Mechanism Thereof: Experiment with Non-Obese Diabetic Mice].

The effects and possible mechanism of quetiapine on glucose regulation of rats

Effect of Paroxetine Combined with Probiotics in Patients with Type 2 Diabetes Mellitus Complicated with Gastrointestinal Dysfunction and Liver Cancer

Effect of Combined Treatment with Clozapine and Metformin on Fasting Blood Glucose, Insulin Level, and Expression of the Glucose Transporter-2 (GLUT2) in Sprague-Dawley Rats.

The DPP-4 Inhibitor Sitagliptin Alters the Gut Microbiota and Prevents Neuronal Damage of Hippocampus in STZ Induced Type 2 Diabetic Rats

Effect of sitagliptin on expression of skeletal muscle peroxisome proliferator-activated receptor γ coactivator-1 α and irisin in a rat model of type 2 diabetes mellitus

Involvement of Pregnane X Receptor in the Impaired Glucose Utilization Induced by Atorvastatin in Hepatocytes.

Microflora Disturbance During Progression of Glucose Intolerance and Effect of Sitagliptin: an Animal Study

The selective serotonin reuptake inhibitors, sertraline and paroxetine, improve islet beta‐cell mass and function in vitro

Combined Contributions of Impaired Hepatic CYP2C11 and Intestinal Breast Cancer Resistance Protein Activities and Expression to Increased Oral Glibenclamide Exposure in Rats with Streptozotocin-Induced Diabetes Mellitus

Experimental Study on the Glucagon-Likepeptide 1 Receptor Agonist Modulation of Insulin Resistance and Hepatic Oxidative Stress in Rats with Diabetes Mellitus Combined with Nonalcoholic Fatty Liver Disease

Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol

Combination of Metformin and Epigallocatechin-3-Gallate Lowers Cortisol, 11β-Hydroxysteroid Dehydrogenase Type 1, and Blood Glucose Levels in Sprague Dawley Rats with Obesity and Diabetes